



1644

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Romero, et al. Examiner: Phuong N. Huynh
Serial No: 10/511,384 Group Art Unit: 1644
Confirmation No: 3767 Docket: 976-19 PCT/US
Filed: October 15, 2004 Dated: April 5, 2007
For: ACTIVE
ANTIANGIOGENIC
THERAPY

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

I hereby certify this correspondence is being deposited with the United States Postal Service as first class mail, postpaid in an envelope, addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on April 5, 2007.

Signed: Joyce Peterson

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In an Office Action mailed March 7, 2007, the Examiner has imposed a Restriction Requirement to one of the following inventions under the provisions of 35 U.S.C. §121 and §372:

1. Claims 1-4, 6-8, and 26, drawn to an immunogenic composition comprising VEGFR1 polypeptides and fragments thereof, administered in the presence or not of a pharmaceutically accepted adjuvant.
2. Claims 1-8, and 26, drawn to an immunogenic composition comprising oligonucleotide encoding VEGFR1 polypeptides and fragments thereof, administered in the presence or not of a pharmaceutically accepted adjuvant.
3. Claims 9-12, 14-16 and 26, drawn to an immunogenic composition comprising VEGFR2 polypeptides and fragments thereof, administered in the presence or not of a pharmaceutically accepted adjuvant.
4. Claims 9-16 and 26, drawn to an immunogenic composition comprising oligonucleotide encoding VEGFR2 polypeptides and fragments thereof,